TP53 and myelodysplastic syndrome: On the other hand, WHO‐5 requires the demonstration of biallelic TP53 inactivation throughout the spectrum of MDS (blasts 0%–19%), thus excluding monoallelic TP53mut MDS with 0%–19% blasts.